Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 27, 2014

Primary Completion Date

June 1, 2023

Study Completion Date

January 16, 2024

Conditions
Chronic Graft Versus Host Disease
Interventions
DRUG

Abatacept

The study will follow a standard 3+3 design with two escalating doses of abatacept to determine the maximum tolerated dose (MTD): 3 mg/kg (dose level 1) and 10 mg/kg (dose level 2). Dose-limiting toxicities (DLTs) are defined as any Grade 3 or 4 toxicities judged to be probably or definitely related to abatacept.

Trial Locations (2)

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Dana-Farber Cancer Institute

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER